AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19552493 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-fracture use of anti-osteoporotic drugs concomitantly with calcium plus vitamin D
Number of subjects: 221
Study 19552493 — intervention group
Group type: COMPARATOR
Intervention: Neither anti-osteoporotic drugs nor prescribed calcium and vitamin D
Number of subjects: 221
Study 17200250 — intervention group
Group type: EXPERIMENTAL
Intervention: SunSafe in the Middle School Years program (intervention)
Number of subjects: 1927
Study 17200250 — intervention group
Group type: COMPARATOR
Intervention: Control communities (control)
Number of subjects: 1927
Study 15280750 — intervention group
Group type: EXPERIMENTAL
Intervention: p-GlcNAc patch
Number of subjects: 33
Study 15280750 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 33
Study 11552913 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (100 mg b.d. for age 2-3 years; 200 mg b.d. for age 4-11 years)
Number of subjects: 110
Study 11552913 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (125 mg b.d. for age 2-5 years; 250 mg b.d. for age 6-11 years)
Number of subjects: 110
Study 8998124 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose recombinant human growth hormone (0.5 international units/kg per week)
Number of subjects: 10
Study 8491104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 0
Study 8491104 — intervention group
Group type: COMPARATOR
Intervention: Standard General Practitioner Care
Number of subjects: 0
Study 3122881 — intervention group
Group type: EXPERIMENTAL
Intervention: Night spent admitting emergency cases
Number of subjects: 12
Study 3122881 — intervention group
Group type: COMPARATOR
Intervention: Night spent on call
Number of subjects: 12
Study 3122881 — intervention group
Group type: COMPARATOR
Intervention: Night spent off duty
Number of subjects: 12
Study 29301450 — intervention group
Group type: EXPERIMENTAL
Intervention: SonoVue (1.5 ml) before HIFU ablation
Number of subjects: 120
Study 29301450 — intervention group
Group type: COMPARATOR
Intervention: Saline (1.5 ml) before HIFU ablation
Number of subjects: 120
Study 27731374 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT, 3 min intervals at 80% and 40% VO2max, n=20)
Number of subjects: 60
Study 27731374 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT, sustained 60% VO2max, n=20)
Number of subjects: 60
Study 27731374 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention, n=20)
Number of subjects: 60
Study 25586282 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (loading dose of 15 μg/kg/min for 20 minutes, maintenance dose of 0.2 μg/kg/min for 6 hours before anesthetic induction)
Number of subjects: 115
Study 25586282 — intervention group
Group type: COMPARATOR
Intervention: Dopamine (10 μg/kg/min) and/or dobutamine (10 μg/kg/min) during weaning from cardiopulmonary bypass
Number of subjects: 115
Study 22456451 — intervention group
Group type: COMPARATOR
Intervention: fMRI activity during face-name paired associative encoding memory paradigm
Number of subjects: 24
Study 19853987 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic approach
Number of subjects: 41
Study 19853987 — intervention group
Group type: COMPARATOR
Intervention: Open approach
Number of subjects: 41
Study 18669722 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 310
Study 18669722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 15562385 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/d)
Number of subjects: 28
Study 15562385 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (1 microg/d)
Number of subjects: 28
Study 12569285 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic pelvic and limb perfusion with 50 mg/m² of melphalan
Number of subjects: 17
Study 12569285 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic pelvic and limb perfusion with 50 mg/m² of melphalan and 25 mg/m² of mitomycin C
Number of subjects: 17
Study 12569285 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic pelvic and limb perfusion (both regimens)
Number of subjects: 17
Study 10551573 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen, balance nitrogen
Number of subjects: 231
Study 10551573 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% oxygen, balance nitrogen
Number of subjects: 231
Study 8558148 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg) with levodopa
Number of subjects: 0
Study 8558148 — intervention group
Group type: COMPARATOR
Intervention: Placebo with levodopa
Number of subjects: 0
Study 1593243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention clinics
Number of subjects: 18
Study 1593243 — intervention group
Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 18
Study 3931495 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 40
Study 3931495 — intervention group
Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 40
Study 3931495 — intervention group
Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 40
Study 30204515 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA injections
Number of subjects: 0
Study 29992713 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 37
Study 29992713 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 37
Study 27618854 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 8399
Study 27618854 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8399
Study 26195199 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid (P-DA)
Number of subjects: 74
Study 26195199 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 74
Study 23577077 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone at a fixed dose with increasing pregabalin doses (Arm A)
Number of subjects: 75
Study 23577077 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin at a fixed dose with increasing oxycodone doses (Arm B)
Number of subjects: 75
Study 23577077 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A
Number of subjects: 75
Study 20529333 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 137
Study 20529333 — intervention group
Group type: COMPARATOR
Intervention: BEXIDEM
Number of subjects: 137
Study 18955945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone, median dose 120 mg/day at endpoint
Number of subjects: 185
Study 16822126 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger environmental coupling (2 beats per cycle)
Number of subjects: 0
Study 16822126 — intervention group
Group type: COMPARATOR
Intervention: Weaker environmental coupling (1 beat per cycle)
Number of subjects: 0
Study 12814389 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid, pyridoxine and cyanocobalamin for 3 months (n = 30)
Number of subjects: 60
Study 12814389 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 30)
Number of subjects: 60
Study 10770814 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective anti-pseudomonal antibiotic treatment (4 treatments per year)
Number of subjects: 60
Study 10770814 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment (3 treatments per year)
Number of subjects: 60
Study 8867773 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Insulin (HI)
Number of subjects: 9
Study 8867773 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine Insulin (PI)
Number of subjects: 9
Study 8867773 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 9
Study 1632252 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 0.5 g x 2
Number of subjects: 106
Study 1632252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 6742612 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (16 mg/day given orally for 7 days)
Number of subjects: 10
Study 6742612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31610946 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct surgeon-controlled image acquisition using a foot pedal (n = 52)
Number of subjects: 100
Study 31610946 — intervention group
Group type: COMPARATOR
Intervention: Indirect image acquisition by a radiology technician (n = 48)
Number of subjects: 100
Study 30562392 — intervention group
Group type: EXPERIMENTAL
Intervention: Magne B6 (Mg–vitamin B6); daily dose 300 mg magnesium and 30 mg vitamin B6
Number of subjects: 264
Study 30562392 — intervention group
Group type: COMPARATOR
Intervention: Magnespasmyl (Mg); daily dose 300 mg magnesium
Number of subjects: 264
Study 30562392 — intervention group
Group type: EXPERIMENTAL
Intervention: Magne B6 (Mg–vitamin B6)
Number of subjects: 264
Study 30562392 — intervention group
Group type: COMPARATOR
Intervention: Magnespasmyl (Mg)
Number of subjects: 264
Study 26297055 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair (LR)
Number of subjects: 119
Study 25599775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine + Propofol (0.5 mg/kg ketamine + 1 mg/kg propofol)
Number of subjects: 70
Study 25599775 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil + Propofol (10 mg/kg alfentanil + 1 mg/kg propofol)
Number of subjects: 70
Study 25599775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine + Propofol
Number of subjects: 70
Study 21617993 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide plus calcium and vitamin D
Number of subjects: 0
Study 21617993 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene plus calcium and vitamin D
Number of subjects: 0
Study 21617993 — intervention group
Group type: COMPARATOR
Intervention: Calcium and vitamin D alone
Number of subjects: 0
Study 19067673 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily for 8 weeks
Number of subjects: 64
Study 17985060 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20g/d during week 1 decreasing to 10g/d at week 2)
Number of subjects: 15
Study 17985060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17985060 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 15
Study 15784478 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (fish oil) enterally (3.3g/day for 5-7 days)
Number of subjects: 28
Study 15784478 — intervention group
Group type: COMPARATOR
Intervention: Control (no n-3 PUFAs)
Number of subjects: 28
Study 11860726 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g dried plums
Number of subjects: 58
Study 11860726 — intervention group
Group type: COMPARATOR
Intervention: 75 g dried apples
Number of subjects: 58
Study 10103297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (250 microg/dose)
Number of subjects: 427
Study 10103297 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (1 mL/dose)
Number of subjects: 427
Study 7576678 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 24
Study 7576678 — intervention group
Group type: COMPARATOR
Intervention: Augustine guide
Number of subjects: 24
Study 7576678 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 24
Study 1712836 — intervention group
Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 125
Study 1712836 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP/CABS
Number of subjects: 125
Study 1712836 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 125
Study 6137307 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine infusion (300 mumol/min for 150 min)
Number of subjects: 18
Study 6137307 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine plus glucose infusion (2.2 mmol/min)
Number of subjects: 18
Study 6137307 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine, somatostatin (7 micrograms/min) and glucagon (1 ng/min) infusion
Number of subjects: 18
Study 30318190 — intervention group
Group type: EXPERIMENTAL
Intervention: Flixweed
Number of subjects: 150
Study 30318190 — intervention group
Group type: EXPERIMENTAL
Intervention: Fig
Number of subjects: 150
Study 30318190 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 29793558 — intervention group
Group type: EXPERIMENTAL
Intervention: Nacadia® NBT (NNBT)
Number of subjects: 84
Study 29793558 — intervention group
Group type: COMPARATOR
Intervention: Specialised Treatment for Severe Bodily Distress Syndromes (STreSS)
Number of subjects: 84
Study 27276804 — intervention group
Group type: EXPERIMENTAL
Intervention: Semitendinous and gracilis transfer
Number of subjects: 29
Study 27276804 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MCL injury)
Number of subjects: 29
Study 27276804 — intervention group
Group type: COMPARATOR
Intervention: Comparison between injury and control groups
Number of subjects: 29
Study 23975354 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute treatment for adolescent depression for 12 weeks followed by an additional 12 weeks of treatment.
Number of subjects: 334
Study 22180621 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment (IT) - 36 weeks of antiretrovirals
Number of subjects: 130
Study 22180621 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment (DT) - no treatment initially
Number of subjects: 130
Study 20209126 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone (CD)
Number of subjects: 1280
Study 20209126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (MQ)
Number of subjects: 1280
Study 20209126 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 1280
Study 20209126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1280
Study 17696268 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer tool designed to elicit preferences based on patient tradeoffs for treatment options.
Number of subjects: 87
Study 17696268 — intervention group
Group type: COMPARATOR
Intervention: Information pamphlet
Number of subjects: 87
Study 15870044 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bypass plus mitral valve repair (group A)
Number of subjects: 38
Study 15870044 — intervention group
Group type: COMPARATOR
Intervention: Coronary bypass alone (group B)
Number of subjects: 38
Study 11960953 — intervention group
Group type: EXPERIMENTAL
Intervention: ACh infusion
Number of subjects: 9
Study 11960953 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 9
Study 11960953 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside (NTP) infusion
Number of subjects: 9
Study 11960953 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA infusion
Number of subjects: 9
Study 11960953 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyramine infusion
Number of subjects: 9
Study 11960953 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP)
Number of subjects: 9
Study 9858440 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg once a day for 14 days
Number of subjects: 1905
Study 9858440 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg once a day for 28 days
Number of subjects: 1905
Study 8582220 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.02mg/kg) and normal saline (200ml)
Number of subjects: 21
Study 8582220 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (200ml)
Number of subjects: 21
Study 2121490 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 240
Study 2121490 — intervention group
Group type: COMPARATOR
Intervention: Tissue plasminogen activator (tPA)
Number of subjects: 240
Study 2121490 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril treatment
Number of subjects: 240
Study 43255 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (0.08 mg/kg i.v.)
Number of subjects: 6
Study 43255 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol (0.4 mg/kg i.v.)
Number of subjects: 6
Study 43255 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (0.4 mg/kg i.v.)
Number of subjects: 6
Study 43255 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (160 mg b.i.d. orally)
Number of subjects: 6
Study 43255 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol (400 mg b.i.d. orally)
Number of subjects: 6
Study 43255 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (40 mg b.i.d. orally)
Number of subjects: 6
Study 31481375 — intervention group
Group type: EXPERIMENTAL
Intervention: s-ketamine (0.25 mg/kg bolus followed by 0.1 mg/kg/hour continuous infusion)
Number of subjects: 62
Study 31481375 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 62
Study 28291960 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with ologen
Number of subjects: 20
Study 28291960 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (MMC)
Number of subjects: 20
Study 25679340 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (1 Hz, 15 min) followed by 45 min physical therapy
Number of subjects: 32
Study 25679340 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 32
Study 23846792 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive sleep (≥ 9 hours per 24-hour period)
Number of subjects: 19136
Study 23846792 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive quantity of sleep (EQS) with distress/impairment
Number of subjects: 19136
Study 23846792 — intervention group
Group type: COMPARATOR
Intervention: Individuals with mood disorder
Number of subjects: 19136
Study 23846792 — intervention group
Group type: EXPERIMENTAL
Intervention: EQS individuals
Number of subjects: 19136
Study 23846792 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with prolonged sleep
Number of subjects: 19136
Study 21851353 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Tooth Mousse (containing CPPs) applied to the right-sided specimen for 1 month
Number of subjects: 40
Study 21851353 — intervention group
Group type: COMPARATOR
Intervention: Placebo mousse applied to the left-sided specimen for 1 month
Number of subjects: 40
Study 21851353 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B) with two enamel specimens placed into the mouth
Number of subjects: 40
Study 19433434 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback
Number of subjects: 20
Study 19433434 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic gloves
Number of subjects: 20
Study 19433434 — intervention group
Group type: COMPARATOR
Intervention: Laser
Number of subjects: 20
Study 19433434 — intervention group
Group type: COMPARATOR
Intervention: Nutritional supplements
Number of subjects: 20
Study 17705695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15-30 mg/day) as add-on therapy to metformin or SU
Number of subjects: 250
Study 17705695 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose combination of metformin (400 mg) and glibenclamide (2.5 mg)
Number of subjects: 250
Study 14762242 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 222
Study 14762242 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 222
Study 14762242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment
Number of subjects: 222
Study 14762242 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-step facilitation
Number of subjects: 222
Study 14762242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 11245756 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group executed a maximal isometric elbow flexion contraction immediately before a maximal elbow extension contraction.
Number of subjects: 26
Study 11245756 — intervention group
Group type: COMPARATOR
Intervention: Control group performed maximal isometric contractions of the elbow extensors.
Number of subjects: 26
Study 11245756 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups performed 5 cycles of a 2‐second contraction with 22‐second rest periods between agonist muscle contractions.
Number of subjects: 26
Study 10660974 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg t.i.d. (n = 14)
Number of subjects: 25
Study 10660974 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 25
Study 10660974 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 25
Study 7887022 — intervention group
Group type: EXPERIMENTAL
Intervention: EcSf2a-2 vaccine (4 doses, 4.1 x 10(8) to 1.1 x 10(9) c.f.u.)
Number of subjects: 119
Study 7887022 — intervention group
Group type: EXPERIMENTAL
Intervention: EcSf2a-2 vaccine
Number of subjects: 119
Study 7887022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 2905245 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine acetate 150 mg
Number of subjects: 60
Study 2905245 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 29758078 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of written information about electrodiagnostic testing
Number of subjects: 128
Study 26787797 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen/tramadol 25 mg/75 mg
Number of subjects: 641
Study 26787797 — intervention group
Group type: COMPARATOR
Intervention: Dexketoprofen 25 mg
Number of subjects: 641
Study 26787797 — intervention group
Group type: COMPARATOR
Intervention: Tramadol 100 mg
Number of subjects: 641
Study 26787797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 641
Study 25619263 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 202
Study 25619263 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacetylmorphine
Number of subjects: 202
Study 25619263 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 202
Study 23421535 — intervention group
Group type: EXPERIMENTAL
Intervention: AF ablation + renal sympathetic denervation (RSDN)
Number of subjects: 0
Study 23421535 — intervention group
Group type: COMPARATOR
Intervention: AF ablation alone (control group)
Number of subjects: 0
Study 21905942 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexTouch® (FT)
Number of subjects: 120